PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28657870
OWN - NLM
STAT- MEDLINE
DA  - 20170628
DCOM- 20170711
LR  - 20170713
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 26
DP  - 2017 Jun 29
TI  - A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.
PG  - 2545-2555
LID - 10.1056/NEJMoa1607033 [doi]
AB  - BACKGROUND: Uncomplicated skin abscesses are common, yet the appropriate
      management of the condition in the era of community-associated
      methicillin-resistant Staphylococcus aureus (MRSA) is unclear. METHODS: We
      conducted a multicenter, prospective, double-blind trial involving outpatient
      adults and children. Patients were stratified according to the presence of a
      surgically drainable abscess, abscess size, the number of sites of skin
      infection, and the presence of nonpurulent cellulitis. Participants with a skin
      abscess 5 cm or smaller in diameter were enrolled. After abscess incision and
      drainage, participants were randomly assigned to receive clindamycin,
      trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for 10 days. The primary
      outcome was clinical cure 7 to 10 days after the end of treatment. RESULTS: We
      enrolled 786 participants: 505 (64.2%) were adults and 281 (35.8%) were children.
      A total of 448 (57.0%) of the participants were male. S. aureus was isolated from
      527 participants (67.0%), and MRSA was isolated from 388 (49.4%). Ten days after 
      therapy in the intention-to-treat population, the cure rate among participants in
      the clindamycin group was similar to that in the TMP-SMX group (221 of 266
      participants [83.1%] and 215 of 263 participants [81.7%], respectively; P=0.73), 
      and the cure rate in each active-treatment group was higher than that in the
      placebo group (177 of 257 participants [68.9%], P<0.001 for both comparisons).
      The results in the population of patients who could be evaluated were similar.
      This beneficial effect was restricted to participants with S. aureus infection.
      Among the participants who were initially cured, new infections at 1 month of
      follow-up were less common in the clindamycin group (15 of 221, 6.8%) than in the
      TMP-SMX group (29 of 215 [13.5%], P=0.03) or the placebo group (22 of 177
      [12.4%], P=0.06). Adverse events were more frequent with clindamycin (58 of 265
      [21.9%]) than with TMP-SMX (29 of 261 [11.1%]) or placebo (32 of 255 [12.5%]);
      all adverse events resolved without sequelae. One participant who received
      TMP-SMX had a hypersensitivity reaction. CONCLUSIONS: As compared with incision
      and drainage alone, clindamycin or TMP-SMX in conjunction with incision and
      drainage improves short-term outcomes in patients who have a simple abscess. This
      benefit must be weighed against the known side-effect profile of these
      antimicrobials. (Funded by the National Institutes of Health; ClinicalTrials.gov 
      number, NCT00730028 .).
FAU - Daum, Robert S
AU  - Daum RS
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Miller, Loren G
AU  - Miller LG
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Immergluck, Lilly
AU  - Immergluck L
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Fritz, Stephanie
AU  - Fritz S
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Creech, C Buddy
AU  - Creech CB
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Young, David
AU  - Young D
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Kumar, Neha
AU  - Kumar N
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Downing, Michele
AU  - Downing M
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Pettibone, Stephanie
AU  - Pettibone S
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Hoagland, Rebecca
AU  - Hoagland R
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Eells, Samantha J
AU  - Eells SJ
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Boyle, Mary G
AU  - Boyle MG
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Parker, Trisha Chan
AU  - Parker TC
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
FAU - Chambers, Henry F
AU  - Chambers HF
AD  - From the University of Chicago Hospitals, Chicago (R.S.D., N.K.); Harbor-UCLA
      Medical Center and Los Angeles BioMedical Research Institute at Harbor-UCLA
      Medical Center, Los Angeles (L.G.M., S.J.E.), and University of California, San
      Francisco-San Francisco General Hospital, San Francisco (D.Y., M.D., H.F.C.);
      Morehouse School of Medicine and Emory University-Grady Memorial Hospital and
      Children's Healthcare of Atlanta, Atlanta (L.I., T.C.P.); Washington University
      School of Medicine-Barnes-Jewish Hospital and St. Louis Children's Hospital, St. 
      Louis (S.F., M.G.B.); Vanderbilt University School of Medicine and Vanderbilt
      University Medical Center, Nashville (C.B.C.); EMMES Corporation, Rockville, MD
      (S.P.); and Cota Enterprises, Meriden, KS (R.H.).
CN  - DMID 07-0051 Team
LA  - eng
SI  - ClinicalTrials.gov/NCT00730028
GR  - UL1 RR033176/RR/NCRR NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Bacterial Agents)
RN  - 3U02EL437C (Clindamycin)
RN  - 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
SB  - AIM
SB  - IM
MH  - Abscess/*drug therapy/therapy
MH  - Adolescent
MH  - Adult
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clindamycin/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Double-Blind Method
MH  - Drainage
MH  - Female
MH  - Humans
MH  - Infant
MH  - Intention to Treat Analysis
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus/isolation & purification
MH  - Prospective Studies
MH  - Skin Diseases, Bacterial/*drug therapy/therapy
MH  - Staphylococcal Skin Infections/drug therapy
MH  - Staphylococcus aureus/isolation & purification
MH  - Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects/*therapeutic use
IR  - Young D
FIR - Young, David
IR  - Campbell A
FIR - Campbell, Andre
IR  - Hansen S
FIR - Hansen, Scott
IR  - Rodriguez R
FIR - Rodriguez, Robert
IR  - Cohen M
FIR - Cohen, Mitchell
IR  - Zeitschel D
FIR - Zeitschel, Deborah
IR  - Volinski J
FIR - Volinski, Joann
IR  - Young K
FIR - Young, Kelly
IR  - Munekata M
FIR - Munekata, Mark
IR  - McKinnell J
FIR - McKinnell, James
IR  - Bolaris M
FIR - Bolaris, Michael
IR  - Sharp L
FIR - Sharp, Linda
IR  - Klein S
FIR - Klein, Stanley
IR  - Dubria M
FIR - Dubria, Merlin
IR  - Manai L
FIR - Manai, Loritta
IR  - Tanoviceanu R
FIR - Tanoviceanu, Roxanne
IR  - Nazarians A
FIR - Nazarians, Arlette
IR  - Flores M
FIR - Flores, Margarita
IR  - Alegria I
FIR - Alegria, Isabel
IR  - Tagudar G
FIR - Tagudar, Grace
IR  - Correa R
FIR - Correa, Ramiro
IR  - Tetangco D
FIR - Tetangco, Dyonne
IR  - Sullivan D
FIR - Sullivan, Diana
IR  - Silverstein T
FIR - Silverstein, Tracey
IR  - Kumar N
FIR - Kumar, Neha
IR  - Self W
FIR - Self, Wes
IR  - Williams D
FIR - Williams, Derek
IR  - Thomsen I
FIR - Thomsen, Isaac
IR  - Toney M
FIR - Toney, Michaela
IR  - Johnson G
FIR - Johnson, Gayle
IR  - Phillips S
FIR - Phillips, Shanda
IR  - Fox S
FIR - Fox, Shanda
EDAT- 2017/06/29 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/29 06:00
AID - 10.1056/NEJMoa1607033 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Jun 29;376(26):2545-2555. doi: 10.1056/NEJMoa1607033.